ArticleInternational journal of chronic obstructive pulmonary disease2018
Increased urinary l-histidine in patients with asthma-COPD overlap: a pilot study.
Article in International journal of chronic obstructive pulmonary disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Clinical Indicators for Asthma-COPD Overlap: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2022Pooled it
- Integrative analysis of transcriptome and metabolome profiles reveals immune-metabolic alterations in pulmonary sarcoidosis.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Body mass index trajectories from birth to early adulthood and lung function development.The European respiratory journal · 2025Article
- Update on metabolomic findings in COPD patients.ERJ open research · 2023Review
- Asthma-COPD Overlap in Clinical Practice (ACO_CP 2023): Toward Precision Medicine.Journal of personalized medicine · 2023Review
- Air pollution, metabolites and respiratory health across the life-course.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Status of Studies Investigating Asthma-Chronic Obstructive Pulmonary Disease Overlap in Korea: A Review.Tuberculosis and respiratory diseases · 2022Review
- Comprehensive Targeted Metabolomic Study in the Lung, Plasma, and Urine of PPE/LPS-Induced COPD Mice Model.International journal of molecular sciences · 2022Article
- ACO (Asthma-COPD Overlap) Is Independent from COPD, a Case in Favor: A Systematic Review.Diagnostics (Basel, Switzerland) · 2021Review
- Metabolic Fingerprinting Uncovers the Distinction Between the Phenotypes of Tuberculosis Associated COPD and Smoking-Induced COPD.Frontiers in medicine · 2021Article
- Metabolomic fingerprinting and systemic inflammatory profiling of asthma COPD overlap (ACO).Respiratory research · 2020Article
- An Updated Overview of Metabolomic Profile Changes in Chronic Obstructive Pulmonary Disease.Metabolites · 2019Review
- Metabolomic signatures of asthma-COPD overlap (ACO) are different from asthma and COPD.Metabolomics : Official journal of the Metabolomic Society · 2019Article
- Metabolomics Identifies Novel Blood Biomarkers of Pulmonary Function and COPD in the General Population.Metabolites · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Asthma-COPD overlap (ACO) is heterogeneous in nature and requires a unified diagnostic approach. We investigated the urinary levels of l-histidine, a precursor of histamine related to inflammatory responses, as a new candidate biomarker for diagnosing this condition. Patients and methods: We performed a prospective multicenter cohort study with retrospective analysis of 107 patients, who were divided into three groups: asthma, COPD, and ACO, according to the Spanish guidelines algorithm. Urinary l-histidine levels were measured using liquid chromatography-mass spectrometry. High-resolution metabolomic analysis, coupled with liquid chromatography-mass spectrometry and followed by multivariate statistical analysis, was performed on urine samples to discriminate between the metabolic profiles of the groups. Results: Urinary l-histidine levels were significantly higher in patients with ACO than in those with asthma or COPD, but the subgroups of ACO, classified according to disease origin, did not differ significantly. High urinary l-histidine level was a significant factor for the diagnosis of ACO even after adjusting for age, sex, and smoking amount. Among patients with airflow obstruction, the urinary l-histidine levels were elevated in patients with a documented history of asthma before the age of 40 years or bronchodilator responsiveness ≥400 mL; bronchodilator responsiveness ≥200 mL of forced expiratory volume in 1 second and exceeding baseline values by 12% on two or more visits; blood eosinophil count ≥300 cells·mm Conclusion: Urinary l-histidine could be a potential biomarker for ACO, regardless of the diversity of diagnostic definitions used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.